Bringing out the circumstances in 2005 which forced amendment to the section 3(d) in Indian Patent Law, 1970, discuss how it has been utilized by the Supreme Court in its judgement in rejecting Novartis' patent application for 'Glivec'. Discuss briefly the pros and cons of the decision.
Explain the TRIPS-driven compulsion behind the 2005 amendment and the purpose of Section 3(d), show precisely how the Supreme Court applied it to Glivec, and give a short balance of the decision's merits and costs.
Common trap: Many answers confuse Section 3(d) with compulsory licensing. A top answer explains the 1 January 2005 TRIPS deadline for product patents, the anti-evergreening logic of 3(d), the Court's reading of 'efficacy' as therapeutic efficacy (bioavailability alone not enough), and then balances access against incentives for incremental innovation.
SyllabusAwareness in the fields of IT, Space, Computers, robotics, nano-technology, bio-technology and issues relating to intellectual property rights.
Model answer
10 marks · 200-word limitThe Patents Act, 1970 granted only process patents for drugs, which allowed Indian firms to make cheap generics. TRIPS obliged India to grant product patents in pharmaceuticals from 1 January 2005, and Section 3(d) was strengthened in the 2005 amendment to make sure that this did not open the door to trivial patents.
- 1995TRIPS: 10-year transition for product patents
- 1998Novartis files Glivec application (mailbox)
- 2005Patents Amendment Act; Section 3(d) strengthened
- 2006Chennai Patent Office rejects application
- 2007Madras HC upholds validity of Section 3(d)
- 2009IPAB upholds rejection under 3(d)
- 1 April 2013Supreme Court rejects patent
Circumstances of the 2005 amendment
- TRIPS deadline: Product patents for food, chemicals and drugs had to be introduced by 2005, and applications held in the 'mailbox' since 1995 had to be examined.
- Fear of evergreening: Parliament worried that companies would extend monopolies by patenting minor changes such as new salts or crystal forms of known drugs.
- The provision: Section 3(d) denies patents to new forms of a known substance unless they show significantly enhanced efficacy; salts, polymorphs and isomers are treated as the same substance.
How the Supreme Court applied it
- The claim: Novartis sought a patent for the beta crystalline form of imatinib mesylate, a known substance used against chronic myeloid leukaemia.
- Meaning of efficacy: For medicines, efficacy means therapeutic efficacy; the claimed higher bioavailability and better flow properties did not prove better therapeutic effect.
- Outcome: The Court held that the claimed form failed Section 3(d) and also lacked novelty and inventive step over the earlier imatinib disclosure.
Pros and cons of the decision
- Pros: Generic imatinib stays available at a fraction of Glivec's price, evergreening is curbed and India keeps its role as pharmacy of the developing world, consistent with the Doha Declaration.
- Cons: MNCs argue it discourages incremental innovation and investment in Indian R&D, invites US pressure under Special 301, and leaves uncertainty about what proof of efficacy suffices.
The judgment confirmed that India will reward genuine innovation but not legal tactics to prolong monopolies. Clear examination guidelines, fast patent offices and incentives for genuine domestic R&D can keep this balance between public health and innovation.
Read more — sources
- OfficialNovartis AG v. Union of India & Others, Supreme Court of India, judgment of 1 April 2013
- OfficialThe Patents Act, 1970 as amended by the Patents (Amendment) Act, 2005 — Section 3(d)
- OfficialWTO Agreement on TRIPS (1994) and the Doha Declaration on TRIPS and Public Health (2001)
More from GS Paper 3 2013
Model answer by the EdiShorts editorial team. It is one well-argued treatment of the question, written to the official word limit — not an official UPSC answer key.